Hyderabad-based Hetero, one of India's leading generic pharmaceutical companies, announced today that it had received the manufacturing and marketing approval for the investigational antiviral medicine Remdesivir from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
Hetero's generic version of Remdesivir will be marketed under the brand name Covifor in India.
Dr B Partha Saradhi Reddy, the Chairman of the Hetero group of companies, said, "In the light of increasing Covid-19 cases in India, the approval of Covifor can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country. We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against Covid-19. This product is made indigenously in line with the 'Make in India' campaign as envisioned by our Prime Minister."
The drug Remdesivir has been granted approval by the DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalized with severe symptoms of the disease. Covifor will be available in a 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.
The product was launched under a licensing agreement with Gilead Sciences Inc to expand access to Covid-19 treatment in low and middle-income countries.